Future work will address these issues; if erlotinib does exhibit therapeutic effects in aged AD mouse models, then we will determine whether erlotinib ameliorates AD pathologies in an EGFR-dependent manner by using an AAV-EGFR-shRNA vector system. The gene discussed is EGFR; the disease is Alzheimer disease.